Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: A multiple criteria decision analysis

J. C. Hsu, D. H. Tang, C. Y. Lu

研究成果: Article同行評審

7 引文 斯高帕斯(Scopus)

摘要

Background Erectile dysfunction (ED) is a common male sexual disorder worldwide. Three oral phosphodiesterase type 5 inhibitors (PDE5Is)-sildenafil, tadalafil and vardenafil-are available for treatment of ED. This study quantitatively evaluated the therapeutic efficacy and safety of these medications to assist treatment decision making. Methods We used multiple criteria decision analysis (MCDA) to assess the totality of risk-benefit of PDE5Is. We created two models: (i) the overall model included 'overall improvement in erections' and 'any adverse events' and (ii) the detailed model included 'erectile function domain', 'ability for sexual intercourse', 'duration of erection last', 'serious adverse events', 'headache', 'flushing' and 'dyspepsia'. We calculated a synthetic utility for each drug accounting for all of its benefits and risks. Results Considering the overall risk-benefit, vardenafil had the highest synthetic utility among three medications; in the order of synthetic utilities: vardenafil (0.568), tadalafil (0.478) and sildenafil (0.437). However, when specific risk and benefit criteria were assessed, tadalafil had the highest synthetic utility (0.602) according to the conjoint evaluation (synthetic utility for vardenafil is 0.491 and sildenafil is 0.442, respectively). The sensitivity analysis based on the uncertainties of weight on risks of any adverse events (including serious adverse events and headache) suggested our results were robust. Conclusions This study provides a useful approach that comprehensively and systematically assesses and compares the risk-benefit of several treatment alternatives. Our study not only rank treatment alternatives by synthetic utilities based on the risk-benefit balance but also compare specific risk and benefit criteria between these medicines. Our results provide valuable evidence that can guide clinicians and patients in making treatment decisions.

原文English
頁(從 - 到)436-443
頁數8
期刊International Journal of Clinical Practice
69
發行號4
DOIs
出版狀態Published - 2015 四月 1

All Science Journal Classification (ASJC) codes

  • Medicine(all)

指紋 深入研究「Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: A multiple criteria decision analysis」主題。共同形成了獨特的指紋。

引用此